PHIO — Phio Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Phio Pharmaceuticals Presents Positive New Data On Systemic Immune Response After Local PH-762 Therapy
Phio Pharmaceuticals Corp reports results for the quarter ended in September - Earnings Summary
Brief: Phio Pharmaceuticals Posts Q3 Loss Per Share Of $0.28
U.S. STOCKS ON THE MOVE-Offerpad Solutions, Leap Therapeutics, Phio Pharmaceuticals
Phio up on promising results from cancer therapy platform study
Brief: Phio Pharmaceuticals Presents Anti-Tumor Immunity Data
Phio Pharmaceuticals Corp reports results for the quarter ended in June - Earnings Summary
Brief: Phio Pharmaceuticals Reports Second Quarter 2021 Financial Results And Provides Business Update
Phio Pharmaceuticals: Up on positive data from cancer therapy platform study
Brief: Phio Pharmaceuticals Presents New In Vivo Data At The 2021 Asco Annual Meeting Showing Dual-Targeting Intasyl Offers Increased Efficacy And Safety Potential Over Other Therapeutic Approaches
Brief: Phio Pharmaceuticals Corp Files For Mixed Shelf Of Up To $100 Mln– SEC Filing
Brief: Phio Pharmaceuticals Reports First Quarter 2021 Financial Results And Provides Business Update
Brief: Phio Presents Positive Data At ASGCT Showing Ph-762 Enhanced Antitumor Efficacy Of CAR-T Cells
Brief: Phio Pharma Expects Current Cash Will Be Sufficient To Fund Currently Planned Operations To Q2 Of 2023
Brief: Phio Pharmaceuticals, AgonOx Inc Announce Collaboration on Development of Cancer Immunotherapies
Brief: Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering Of Common Stock Priced At-The-Market
Brief: Phio Pharmaceuticals Says Files Prospectus Relates To Resale Of Up To 8.3 Million Shares By Selling Stockholder - SEC Filing
Brief: Phio Pharmaceuticals Reports Q3 Loss Per Share Of $0.40
Brief: Phio Presents New Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL At SITC 2020